Literature DB >> 17988903

Interobserver and intraobserver variability of interpretation of CT-angiography in patients with a suspected abdominal aortic aneurysm rupture.

L L Hoornweg1, W Wisselink, A C Vahl, J A Reekers, O M van Delden, D A Legemate, R Balm.   

Abstract

PURPOSE: To assess interobserver and intraobserver agreement on presence of rupture and determining suitability for endovascular repair (EVAR) on CT angiography (CTA) of patients with a suspected ruptured abdominal aortic aneurysm (RAAA).
METHODS: For the Amsterdam Acute Aneurysm study, a randomised multicenter trial (ISRCTN66212637), we register all patients with suspected RAAA in the Amsterdam region. For the current analysis 51 consecutive patients were included from this prospective database. Pre operative CT scans were assessed twice with a six-week interval by three vascular surgeons and two interventional radiologists. Variables recorded were presence of rupture, diameter and length of the infrarenal aortic neck, diameters of both iliac arteries and final judgement on anatomical suitability for EVAR. Kappa values for dichotomous outcomes were calculated as a measure of agreement above chance. Continuous outcomes were investigated by calculating the intraclass correlation coefficient (ICC) and by Bland-Altman plots.
RESULTS: For presence of rupture group kappa was 0.59 (CI: 0.42-0.77). The group kappa of suitability for EVAR was 0.38 (CI: 0.24-0.51). The ICC for diameter and length of the infrarenal aortic neck and diameters of left and right iliac arteries were 0.40 (CI: 0.26-0.56), 0.47 (CI: 0.32-0.62), 0.61 (CI: 0.48-0.74) and 0.35 (CI: 0.21-0.50) respectively. The Bland-Altman plots confirmed the large variation among observers. Intraobserver kappa ranged from 0.57-0.78 for presence of rupture and 0.40-0.80 for suitability for EVAR.
CONCLUSION: Moderate interobserver agreement was found for presence of rupture and fair agreement for suitability for EVAR. Intraobserver agreement ranged from moderate to almost perfect. Based on this data, optimization of the protocol is mandatory to identify uniform measuring techniques of well defined anatomical criteria for endovascular repair of ruptured aneurysms.

Entities:  

Mesh:

Year:  2007        PMID: 17988903     DOI: 10.1016/j.ejvs.2007.09.017

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  6 in total

1.  Three-dimensional aortic aneurysm model and endovascular repair: an educational tool for surgical trainees.

Authors:  Chumpon Wilasrusmee; Jesada Suvikrom; Jackrit Suthakorn; Panuwat Lertsithichai; Kriskrai Sitthiseriprapip; Napaphat Proprom; Dilip S Kittur
Journal:  Int J Angiol       Date:  2008

2.  Management of symptomatic abdominal aortic aneurysms following emergency computed tomography.

Authors:  Masahiro Matsushita; Teruo Ikezawa; Masayuki Sugimoto; Akihito Idetsu
Journal:  Surg Today       Date:  2013-02-16       Impact factor: 2.549

3.  Automated quantification of aortoaortic and aortoiliac angulation for computed tomographic angiography of abdominal aortic aneurysms before endovascular repair: preliminary study.

Authors:  Bhargav Raman; Raghav Raman; Sandy Napel; Geoffrey D Rubin
Journal:  J Vasc Interv Radiol       Date:  2010-10-08       Impact factor: 3.464

4.  Endovascular strategy or open repair for ruptured abdominal aortic aneurysm: one-year outcomes from the IMPROVE randomized trial.

Authors: 
Journal:  Eur Heart J       Date:  2015-04-07       Impact factor: 29.983

Review 5.  Individual-patient meta-analysis of three randomized trials comparing endovascular versus open repair for ruptured abdominal aortic aneurysm.

Authors:  M J Sweeting; R Balm; P Desgranges; P Ulug; J T Powell
Journal:  Br J Surg       Date:  2015-06-24       Impact factor: 6.939

6.  Comparative clinical effectiveness and cost effectiveness of endovascular strategy v open repair for ruptured abdominal aortic aneurysm: three year results of the IMPROVE randomised trial.

Authors: 
Journal:  BMJ       Date:  2017-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.